Mirati Therapeutics Inc
Aperta
SettoreSettore sanitario
0
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
Massimo
Raccomandazioni | Neutrale |
|---|---|
Previsioni per 12 mesi | -0.05% downside |
Notizie sul Sentiment di mercato
By Acuity
50%
50%
166 / 347 Classifica in Healthcare
Mirati Therapeutics Inc Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Notizie correlate
Confronto tra pari
Modifica del prezzo
Mirati Therapeutics Inc Previsione
Obiettivo di Prezzo
By TipRanks
-0.05% in calo
Previsioni per 12 mesi
Media 58.67 USD -0.05%
Alto 59 USD
Basso 58 USD
Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Mirati Therapeutics Inc - Dist negli ultimi 3 mesi.
Sentiment
By Acuity
166 / 347 Classifica in Settore sanitario
Notizie sul Sentiment di mercato
Neutral
Volatilità
Sotto la media
Volume delle notizie (RCV)
Sotto la media
Notizie finanziarie
Spese di vendita e di amministrazione
Spese operative
Utile prima delle imposte
Vendite
Costo delle vendite
Utile lordo sulle vendite
EBITDA
Utile operativo
$
Chi Siamo Mirati Therapeutics Inc
Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.
